MRI Confirms BriaCell's Effectiveness in Metastatic Breast Cancer with Eye Protrusion

BriaCell Therapeutics, a clinical-stage biotechnology firm, has reported impressive results from their Phase 2 study involving Bria-IMT™, an immunotherapy treatment designed for advanced metastatic breast cancer. The company has shared MRI images that demonstrate a significant reduction in the size of a tumor located behind the eye, a region that is notoriously challenging to treat. The patient, who had previously undergone seven unsuccessful treatment regimens, including antibody-drug conjugate therapy, experienced a notable decrease in proptosis (eye bulging) and ocular pain after only three cycles of Bria-IMT™ treatment.

Dr. William V. Williams, President and CEO of BriaCell, expressed excitement over the tumor reduction observed in a patient with a difficult-to-treat condition. He highlighted the robust anti-tumor activity of Bria-IMT™, especially in reaching tumors in the eye orbit. The treatment was well-tolerated, and the patient continued to receive it. The MRI images provided a visual representation of the treatment's effectiveness, with the eye regaining its normal position post-treatment, and the tumor's reduction being clearly indicated.

BriaCell had previously reported a similar case with an eye-bulging orbital tumor that resolved after the patient had failed multiple prior treatments. These responses contribute to the 71% intracranial objective response rate (iORR) observed in breast cancer patients with CNS metastases treated with Bria-IMT™.

Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer, emphasized the importance of developing novel treatments for metastatic breast cancer, a condition with poor survival rates despite recent therapeutic advancements. The Bria-IMT™ combination regimen is currently in a pivotal Phase 3 study for advanced breast cancer, offering hope for improved patient outcomes.

BriaCell's commitment to developing innovative immunotherapies aims to transform cancer care, and their ongoing studies are crucial for evaluating the potential of Bria-IMT™ in treating metastatic breast cancer, especially in cases where traditional treatments have failed.